Valeant’s chief, J. Michael Pearson, has slimmed down the company, but been an aggressive acquirer, spending more than $19 billion on companies. Valeant now has Allergan, maker of Botox, in its sights.
By DAVID GELLES, NY Times: Business
Wed, 04/23/2014 - 6:21pm
Valeant’s chief, J. Michael Pearson, has slimmed down the company, but been an aggressive acquirer, spending more than $19 billion on companies. Valeant now has Allergan, maker of Botox, in its sights.